DETAILED NOTES ON ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION

In Segment A, contributors will get distinct doses and schedules of oral ABBV-744 tablet to detect Harmless dosing routine. Further participants will be enrolled within the recognized monotherapy dosign program. In Segment B, contributors will get oral ruxolitinib and ABBV-744 will likely be offered as "increase-on" therapy. In Section C, participa